Compared side by side

Semaglutide vs BPC-157: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

They do different jobs: semaglutide is a weekly GLP-1 receptor agonist, FDA-approved for type 2 diabetes and weight management, and BPC-157 is a peptide derived from a protein in human gastric juice that, in animal studies, protects the gut lining and speeds tendon, ligament and muscle repair. Semaglutide averaged about 15% weight loss at 68 weeks in its main trial; BPC-157’s human studies so far are three small uncontrolled pilots. Commonly reported: nausea worst in the first days after each semaglutide dose step, and a calmer gut on BPC-157, which the library lists beside semaglutide for GI support.

Side by side

ComparedSemaglutideBPC-157
CategoryMetabolic & GLP-1Healing & recovery
Also known asOzempic, WegovyBody Protection Compound 157, BPC157
What it isA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.A peptide derived from a protective protein in your stomach.
How it worksGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.
Commonly reportedThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
Studied rangeFDA label: 0.25–2.4 mg, starting dose 0.25 mg.Research range: 200–500 mcg. Studied in research — not a recommendation.
How oftenWeekly SubQOnce or twice daily
Half-life~1 week (FDA label)~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)
RouteSubQ injectionSubQ injection, IM injection, Oral (less studied)
Typical runFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.
EvidenceEstablished: clinical trials or FDA-approved use existsEmerging: primarily preclinical / limited human data
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis riskNausea (rare), injection site irritation, vivid dreams, dizziness

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide or BPC-157? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Semaglutide

  • Day 1–28 · 0.25 mg Gut is adapting
  • Day 29–56 · 0.5 mg Appetite shifts are real now
  • Day 57–112 · 1 mg Clinically useful weight loss kicks in
  • Day 113–140 · 1.7 mg Max submaximal step
  • Day 141–364 · 2.4 mg Full dose — the working dose
  • Day 365+ Plateau territory — new baseline

Every card for semaglutide, with its sources

BPC-157

  • Day 1–7 Week one: early hints, for some
  • Day 7–14 Pain often starts to ease
  • Day 14–21 Pain often eases by week three
  • Day 21–28 Many report a calmer gut
  • Day 28–42 The slower part of repair
  • Day 42–56 Six weeks in: taking stock
  • Day 84+ Past week 12, the data runs thin

Every card for BPC-157, with its sources

Together or one or the other

Semaglutide and BPC-157 are a common stack: semaglutide lists BPC-157 among its common stacks.

Community · Semaglutide

Why people add BPC-157 to Sema

Sema titration comes with GI symptoms, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: fewer GI side effects in the first weeks after each step-up.

Questions people ask

How long do semaglutide and BPC-157 last?

The half-life of semaglutide is ~1 week (FDA label). The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes).

How often are semaglutide and BPC-157 taken?

Semaglutide: weekly SubQ. Route: SubQ injection. BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied).

How are semaglutide and BPC-157 dosed in research?

The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for BPC-157 is 200–500 mcg. Studied in research — not a recommendation.

What are the common side effects of semaglutide and BPC-157?

For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For BPC-157: nausea (rare), injection site irritation, vivid dreams, dizziness.

Are semaglutide and BPC-157 taken together?

Semaglutide and BPC-157 are a common stack: semaglutide lists BPC-157 among its common stacks. Sema titration comes with GI symptoms, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: fewer GI side effects in the first weeks after each step-up.

Each one in full

Track it in the app

PepVault for iPhone

Taking semaglutide or BPC-157? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo